Last reviewed · How we verify

Osteoarthritis of hip — Treatment Landscape & Competitive Intelligence

Osteoarthritis of hip (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Osteoarthritis of hip, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Joycle diclofenac etalhyaluronate sodium Seikagaku Corporation Prostaglandin E2 receptor EP2 subtype

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Seikagaku Corporation · 1 drug in Osteoarthritis of hip

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Osteoarthritis of hip:

Cite this brief

Drug Landscape (2026). Osteoarthritis of hip — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/osteoarthritis-of-hip. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing